eMedicine Specialties > Dermatology > Diseases of Pigmentation
Argyria: Treatment & Medication
Updated: Mar 13, 2009
- Overview
- Differential Diagnoses & Workup
- Treatment & Medication
- Follow-up
Treatment
Medical Care
- Treatment with depigmenting preparations is not satisfactory; however, according to some reports, 5% hydroquinone treatment may reduce the number of silver granules in the upper dermis and around sweat glands and diminish the number of melanocytes.
- Chelation attempts to remove silver from the body have been unsuccessful.
- Sunscreens and opaque cosmetics may be helpful in preventing further pigmentary darkening and aid in masking obvious discoloration.
Surgical Care
- Rhee et al reported on the treatment of argyria caused by colloidal silver ingestion using the Q-switched 1064-nm Nd:YAG laser.17
Medication
Selenium and sulfur have been shown to have favorable modifying effects on the metabolism and toxicity of silver by forming complexes with silver. Silver selenide is highly insoluble in vivo, and this effectively reduces the availability of monovalent silver to interfere with normal enzymatic activities in tissues. However, the silver-sulfur complexes formed in vivo do not seem as stable as silver-selenium complexes.
Pigment agents
According to reports, a 4% hydroquinone treatment could reduce the number of silver granules in the upper dermis and around sweat glands and reduce the number of melanocytes; however, no completely satisfactory treatment modalities exist and some pigmentation remains permanently.
Hydroquinone (Eldopaque-Forte, Solaquin Forte, Lustra)
Topical application produces a reversible depigmentation of the skin by the inhibition of the enzymatic oxidation of tyrosine to 3,4-dihydroxyphenylalanine and suppression of melanocyte metabolic process.
Adult
Apply to affected areas bid, in the morning and before bedtime
Pediatric
<12 years: Not established
None reported
Documented hypersensitivity; sunburns
Pregnancy
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions
Avoid solar exposure; not for ophthalmic, nasal, or otic use; application area should not exceed that of face, neck, hands, or arms; long-term use in dark-skinned individuals may lead to a localized form of ochronosis
More on Argyria |
| Overview: Argyria |
| Differential Diagnoses & Workup: Argyria |
Treatment & Medication: Argyria |
| Follow-up: Argyria |
| References |
| « Previous Page | Next Page » |
References
Bouts BA. Images in clinical medicine. Argyria. N Engl J Med. May 20 1999;340(20):1554. [Medline].
Fung MC, Bowen DL. Silver products for medical indications: risk-benefit assessment. J Toxicol Clin Toxicol. 1996;34(1):119-26. [Medline].
Gulbranson SH, Hud JA, Hansen RC. Argyria following the use of dietary supplements containing colloidal silver protein. Cutis. Nov 2000;66(5):373-4. [Medline].
Brandt D, Park B, Hoang M, Jacobe HT. Argyria secondary to ingestion of homemade silver solution. J Am Acad Dermatol. Aug 2005;53(2 Suppl 1):S105-7. [Medline].
Gaslin MT, Rubin C, Pribitkin EA. Silver nasal sprays: misleading Internet marketing. Ear Nose Throat J. Apr 2008;87(4):217-20. [Medline].
Legat FJ, Goessler W, Schlagenhaufen C, Soyer HP. Argyria after short-contact acupuncture. Lancet. Jul 18 1998;352(9123):241. [Medline].
Rackoff EM, Benbenisty KM, Maize JC, Maize JC Jr. Localized cutaneous argyria from an acupuncture needle clinically concerning for metastatic melanoma. Cutis. Nov 2007;80(5):423-6. [Medline].
Prescott RJ, Wells S. Systemic argyria. J Clin Pathol. Jun 1994;47(6):556-7. [Medline].
Bianchi L, Orlandi A, Di Stefani A, Ricci R, Chimenti S. "Familial" generalized argyria. Arch Dermatol. Jun 2006;142(6):789-90. [Medline].
Menaguale G, Fazio R, Fazio M. Argyria: a case following the prolonged use of a rhinologic drug. Esper Dermatol (Roma). 2003;4:299-303.
Fisher NM, Marsh E, Lazova R. Scar-localized argyria secondary to silver sulfadiazine cream. J Am Acad Dermatol. Oct 2003;49(4):730-2. [Medline].
Shelley WB, Shelley ED, Burmeister V. Argyria: the intradermal "photograph," a manifestation of passive photosensitivity. J Am Acad Dermatol. Jan 1987;16(1 Pt 2):211-7. [Medline].
Graham SA, O'Meara JM. The feasibility of measuring silver concentrations in vivo with x-ray fluorescence. Phys Med Biol. Aug 7 2004;49(15):N259-66. [Medline].
Lee SM, Lee SH. Generalized argyria after habitual use of AgNO3. J Dermatol. Jan 1994;21(1):50-3. [Medline].
Robinson-Bostom L, Pomerantz D, Wilkel C, et al. Localized argyria with pseudo-ochronosis. J Am Acad Dermatol. Feb 2002;46(2):222-7. [Medline].
Sato S, Sueki H, Nishijima A. Two unusual cases of argyria: the application of an improved tissue processing method for X-ray microanalysis of selenium and sulphur in silver-laden granules. Br J Dermatol. Jan 1999;140(1):158-63. [Medline].
Rhee DY, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK. Treatment of argyria after colloidal silver ingestion using Q-switched 1,064-nm Nd:YAG laser. Dermatol Surg. Oct 2008;34(10):1427-30. [Medline].
Further Reading
Keywords
argyria, universal argyria, localized argyria, ingestion of silver salts, contact with silver salts, staining of skin, silver staining
Treatment & Medication: Argyria